Utah House advances HB174 to permanently ban youth gender-affirming care after lengthy floor debate
The Utah House of Representatives voted 54–15 on Feb. 5 to pass first substitute HB 174, a bill that would permanently ban gender-affirming medical care for transgender minors, following a lengthy and contentious floor debate that underscored deep divisions over science, medical ethics, and youth mental health.
Sponsored by Rep. Rex P. Shipp, R-Cedar City, HB 174 builds on SB 16, a 2023 law that prohibited gender-affirming surgeries for minors and imposed a temporary moratorium on puberty blockers and cross-sex hormones. While SB 16 allowed youth already receiving care to continue treatment under a grandfather clause, HB 174 would make the moratorium permanent and require those treatments to end by January 28, 2027.
Presenting the bill, Shipp framed gender dysphoria as a mental health condition that should be addressed through psychological care rather than medical intervention. He cited potential risks of puberty blockers and hormone therapy, including impacts on bone density, fertility, neurocognitive development, and cardiovascular health. Shipp also sharply criticized a Utah Department of Health and Human Services report mandated under SB 16, arguing it failed to meet the standards of a true systematic medical review and showed significant bias.
“These kids do need care,” Shipp told lawmakers. “But we shouldn’t be damaging physically healthy bodies. As minors, they should not be making life-altering decisions.”
Rep. Jennifer Dailey-Provost delivered the most detailed opposition testimony of the debate, offering an in-depth scientific rebuttal that challenged both the evidence cited by supporters and the framing of the issue itself. Dailey-Provost argued that proponents of HB 174 relied on selective citation, cherry-picked studies, and mischaracterizations of medical consensus to justify sweeping restrictions.
She warned lawmakers against equating low-certainty evidence with evidence of harm, stressing that uncertainty is common across pediatric medicine because of ethical limitations on conducting randomized controlled trials involving children. Holding transgender healthcare to a higher evidentiary standard than other pediatric treatments, she argued, creates an unfair and inconsistent benchmark.
Dailey-Provost also pushed back forcefully against claims that European countries have banned gender-affirming care. She noted that countries such as Sweden, Finland, and the United Kingdom continue to allow treatment through tightly regulated clinical pathways, rather than imposing blanket bans. The widely cited UK Cass Review, she said, acknowledges shortcomings in available evidence but does not recommend prohibiting care outright.
She further challenged assertions about detransition and suicide rates, arguing that opponents misrepresented data by ignoring a wider perspective. According to Dailey-Provost, studies often cited to claim high detransition rates rely on small samples and fail to account for confounding factors such as social stigma, family rejection, economic instability, and lack of access to supportive care. She added that higher suicide risk among transgender youth is more strongly linked to discrimination and denial of care than to medical treatment itself.
“A counterfactual is not a neutral outcome,” Dailey-Provost said, stressing that untreated gender dysphoria carries documented mental health risks. “Denying healthcare to a marginalized, at-risk population of children is always a mistake.”
She concluded by warning lawmakers that basing public policy on what she described as “bad science” would result in real harm to vulnerable families across the state.
Other lawmakers framed their support for the bill as an issue of caution rather than ideology. Rep. Clancy said the seriousness and long-term consequences of healthcare treatments justified delaying such decisions until adulthood.
After the debate was cut short by a successful motion for the previous question, the House approved HB 174. The bill now moves to the Utah Senate, where it is expected to face continued scrutiny from medical professionals, LGBTQ+ advocates, and civil rights groups who warn it will further restrict access to care for transgender youth in the state.
